To investigate the levels of dynactin 2 (DCTN2) and paired box gene 8 (PAX8) in prostatic carcinoma (PCa) tissues and their relationship with clinicopathological features and prognosis.
Approach:
Study Design: A total of 103 patients with PCa were selected, and immunohistochemical staining was used to detect DCTN2 and PAX8 expression levels in tissue samples.
Data Analysis: Associations of DCTN2 and PAX8 expression with clinicopathological characteristics and prognosis were analyzed.
Key Findings:
Positive expression rates of DCTN2 and PAX8 were higher in PCa tissues than in adjacent tissues (P<0.05).
DCTN2 and PAX8 expression correlated with tumor differentiation grade, lymph node metastasis, clinical stage, distant metastasis, preoperative PSA, and Gleason score (P<0.05).
3-year progression-free survival rate was lower for positive DCTN2 and PAX8 expression compared to negative expression (P = 0.002).
Factors affecting poor prognosis included lymph node metastasis, clinical stage, Gleason score, DCTN2, and PAX8 expression (P<0.05).
Interpretation:
DCTN2 and PAX8 expression levels are associated with clinicopathological features and prognosis in patients with prostate cancer.
Limitations:
The study was limited to a single institution and included a relatively small sample size, which may affect the generalizability of the results.
The follow-up duration was limited to 3 years, which may not capture long-term outcomes.
Conclusion:
Elevated expression rates of DCTN2 and PAX8 in PCa tissues are associated with adverse clinicopathological features and prognosis.
